SWOG clinical trial number
SWOG-9213
A Phase II Evaluation of Fazarabine for Patients with "Poor Prognosis” Extensive Stage Small Cell Lung Cancer
Closed
Phase
Accrual
10%
Abbreviated Title
A Phase II Evaluation of Fazarabine for Patients with "Poor Prognosis” Extensive Stage Small Cell Lung Cancer
Activated
06/15/1993
Closed
06/15/1994